Introduction {#Sec1}
============

Primary hypertrophic cardiomyopathy (HCM) is characterized by asymmetrical hypertrophy of the left ventricle and septum, without underlying cardiac or vascular abnormalities (Richardson et al. [@CR11]) The prevalence of primary HCM is 0.2% in the general population and in about 60% of the cases a mutation is identified in one of the 13 genes encoding the sarcomeric proteins (Ramaraj [@CR8]; Richard et al. [@CR9], [@CR10]). The clinical presentation and development of HCM is very diverse, ranging from no symptoms at all to end--stage heart failure. Primary dilated cardiomyopathy (DCM) is characterized by eccentric remodelling of the heart (Richardson et al. [@CR11]). Although 20--48% of DCM cases are familial, only a small number of mutations are known to date (Chang and Potter [@CR4]). The asymmetric remodelling observed in HCM and the variable geno- and phenotypes in familial HCM and DCM raise the question how representative small cardiac tissue sample are for the region of the left ventricle (LV) they are taken from.

A characteristic feature of end-stage heart failure is down regulation and desensitization of the β-adrenergic receptor pathway, as a consequence of chronic stimulation of the sympathetic system (Bristow et al. [@CR2]; Hamdani et al. [@CR7]). Consequently, the downstream sarcomeric target proteins cardiac troponin I (cTnI) and myosin binding protein C (cMyBP-C) may become less phosphorylated by protein kinase A (PKA) (Bodor et al. [@CR1]; El Armouche et al. [@CR6]; van der Velden et al. [@CR12]; van Dijk et al. [@CR13]). Therefore, we compared the variability in phosphorylation of the β-adrenergic target proteins cTnI and cMyBP-C within the left ventricle from HCM and DCM tissue samples to cardiac tissue from donors.

Methods {#Sec2}
=======

Cardiac tissue {#Sec3}
--------------

Tissue from the free LV wall from end-stage heart failure patients clinically characterized with familial hypertrophic (*n* = 5) or dilated (*n* = 5) cardiomyopathy was obtained during cardiac transplantation surgery. Control cardiac LV tissue was obtained from donor hearts (*n* = 5) for which no suitable transplant recipient was found. The donors had no history of cardiac disease, a normal ECG and normal ventricular function on echocardiography performed within 24 h prior to heart explantation.

The tissue was collected in cold cardioplegic solution, divided into pieces of approximately 2 g wet weight and immediately frozen in liquid nitrogen. Samples were obtained after informed consent and with approval of the local ethical committee (St. Vincent's Hospital Human research Ethics Committee: File number H03/118; Title: Molecular Analysis of Human heart Failure).

Protein phosphorylation {#Sec4}
-----------------------

From each patient, four or five small pieces of about 0.5--1 mg wet weight were taken randomly from one LV tissue sample. All samples were treated with trichloro acetic acid prior to protein analysis to preserve the endogenous phosphorylation status of the sarcomeric proteins. Proteins in cardiac tissue homogenates were separated on 4--15% Tris-HCl gels (Biorad) (Fig. [1](#Fig1){ref-type="fig"}). Each sample was run in duplo on the gels. To detect protein phosphorylation, the gels were stained with ProQ Diamond. Subsequently the gels were stained with SYPRO Ruby to determine protein content. Staining of the gels was visualized using the Las-3000 Image Reader (Fuji; 460/605 nm) and analyzed with AIDA, as described before (Zaremba et al. [@CR14]). cMyBP-C phosphorylation level was expressed relative to cMyBP-C content and cTnI phosphorylation to α-actinin content to correct for loading differences.Fig. 1A representative gradient gel stained with ProQ Diamond and SYPRO Ruby, demonstrating the phosphorylation status of cMyBP-C and cTnI. MWM indicates molecular weight marker

Data analysis {#Sec5}
-------------

Data are presented as mean ± standard error of the mean (SEM). The variance within each sample was expressed as the coefficient of variation. A comparison was made between the mean coefficient of variation in HCM, DCM and donor with one-way ANOVA. *P* \< 0.05 was considered significant.

Results {#Sec6}
=======

Inter- and intra-patient variability can partly be attributable to imprecision of the technique used to determine protein phosphorylation. The precision of the technique was estimated by analyzing the difference between duplicate measurements. The coefficient of variation of the duplicate measurements of cMyBP-C phosphorylation was higher in HCM and DCM samples compared to donor (38 ± 10 and 39 ± 9 vs. 11 ± 2%, respectively). Lower variability was seen in cTnI phosphorylation, though again the coefficient of variation was higher in HCM and DCM than in donor (17 ± 3 and 24 ± 6 vs 10 ± 2%, respectively). The variabilities between duplicate measurements are inversely related with the absolute phosphorylation levels (i.e. higher variability on low phosphorylation levels), indicating that differences in variability are largely accountable to noise in the measurement.

The variability within each LV sample was assessed by determining how much each of the 4--5 randomly selected tissue samples differed from the average of that heart and expressed as the coefficient of variation. The phosphorylation of cMyBP-C and cTnI in the different tissue samples within the three groups is shown in Fig. [2](#Fig2){ref-type="fig"}, with the coefficient of variation depicted above the bars for each individual. The coefficient of variation of cMyBP-C phosphorylation ranged from 6 to 20% in donor, from 9 to 138% in HCM and from 0 to 43% in DCM samples (Fig. [2](#Fig2){ref-type="fig"}a, b, c). Similarly, the variability in cTnI phosphorylation ranged from 15 to 35% among donor, from 9 to 22% between HCM and from 19 to 45% in DCM samples (Fig. [2](#Fig2){ref-type="fig"}d, e, f).Fig. 2Intra-heart variability in protein phosphorylation. **a--c** cMyBP-C phosphorylation. **d--f** cTnI phosphorylation. The coefficient of variation is indicated above the *bars* for each heart

The variability within LV samples from each group was compared using one-way ANOVA (Fig. [3](#Fig3){ref-type="fig"}). The average coefficient of variation of cMyBP-C phosphorylation was slightly higher in HCM (46 ± 23%) and DCM (21 ± 6%) compared to donor (11 ± 3%), but the difference was not significant (Fig. [3](#Fig3){ref-type="fig"}a, closed symbols). The relatively wide spread in variability of cMyBP-C phosphorylation in HCM and DCM can be explained by the zero phosphorylation level in some of the samples from HCM 1 and DCM 3. The cMyBP-C phosphorylation in these samples was presumably below the detection level of the ProQ Diamond stain. Exclusion of HCM 1 and DCM 3 lowered the average coefficient of variation of cMyBP-C phosphorylation in HCM to 23 ± 6%, while the mean coefficient of variation became slightly higher in DCM (25 ± 5%). Furthermore, the large SEM of the coefficient of variation in HCM was lowered. Even after exclusion of HCM 1 and DCM 3 the difference in average variance between HCM and DCM and donor remained not significant (Fig. [3](#Fig3){ref-type="fig"}a, open symbols). Accordingly, it can be concluded that the average coefficient of variation for cTnI phosphorylation (Fig. [3](#Fig3){ref-type="fig"}b; closed symbols) did not differ significantly among groups (14 ± 3% in HCM; 28 ± 4% in DCM and 24 ± 4% in donor).Fig. 3The coefficient of variation, a measure of how much the individual values of each heart differed from the mean, was on average not significantly different between donor, HCM and DCM for the phosphorylation status of cMyBP-C **(a)** or cTnI **(b)**(*closed symbols*). Within the analysis of cMyBP-C phosphorylation, exclusion of outliers (HCM 1 and DCM 3) lowered the mean coefficient of variation and the SEM in HCM, while the average coefficient of variation of the DCM group was slightly increased (as indicated by the *arrow*, *open symbols*). After exclusion of the outliers there was still no significant difference in coefficient of variation among the groups. Groups were compared by one-way ANOVA, *P* \< 0.05 was considered significant

The average phosphorylation of cMyBP-C was lower in HCM and DCM than in donor (HCM 0.2 ± 0.05, DCM 0.1 ± 0.03 and donor 0.4 ± 0.01). Post hoc analysis indicated that cMyBP-C phosphorylation was significantly lower in DCM compared to donor. The average cTnI phosphorylation was significantly lower in both HCM and DCM compared to donor (0.4 ± 0.01 and 0.6 ± 0.4 vs. 1.5 ± 0.1, respectively).

Discussion {#Sec7}
==========

In this study the variability in phosphorylation of β-adrenergic target proteins within patients with HCM and DCM was determined. A comparison was made between protein phosphorylation status of cMyBP-C and cTnI in HCM and DCM patients and in donor.

Although some variation was found between different pieces from one heart sample, this variation was not significantly different in HCM and DCM samples compared to donor samples. Furthermore, the coefficient of variation of the cMyBP-C and cTnI phosphorylation in hearts was in the same range as the variability of the duplicate measurements on the ProQ stained gels, indicating that part of the variability within hearts can be ascribed to imprecision of the technique. Since the samples weighted approximately 2 g, our results do not rule out the possibility of transmural differences in protein phosphorylation (Cazorla et al. [@CR3]; Davis et al. [@CR5]).

Figure [2](#Fig2){ref-type="fig"} demonstrates inter-patient variability in protein phosphorylation. Furthermore, it can be appreciated that in general the phosphorylation of cMyBP-C and cTnI is lower in HCM and DCM compared to donor, in accordance with previous data obtained in ischemic heart disease (van der Velden et al. [@CR12]).

In conclusion, we demonstrate comparable variability of cMyBP-C and cTnI phosphorylation within hearts from HCM and DCM patients and donors, indicating that, within the precision of our measurements, small left ventricular tissue samples of end stage-failing hearts from primary cardiomyopathy patients are representative for the region they were taken from.
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